Steris Plc, a top growth stock in the long term, has caught the attention of Wall Street analysts, with positive views mainly driven by MedTech momentum. The company's recent earnings calls signify consistently robust financial performance, with Q1, Q3 and Q4 of 2025 witnessing strong revenue growth. Additionally, their Q1 2026 earnings saw 9% revenue growth and an updated financial outlook that triggered an upward surge in the stock. Strategic acquisitions are predicted to boost the Steris stock amid prevailing macro issues. An important development mentioned is the CFO transition, where Michael J. Tokich will be succeeded by Karen L. Burton. Steris is expected to benefit from plans to bring pharmaceutical manufacturing back to the U.S, adding more appeal to hold the stock. Another highlight is the quarterly dividend increase for the 20th consecutive year and their position as a leader in the healthcare sterilization industry. However, the company also faces margin challenges and international revenue concerns. Although some coverage holds a 'buy' rating, other analysts recommend holding the stock, indicating a mixed-market sentiment.
Steris Plc STE News Analytics from Wed, 05 Dec 2018 08:00:00 GMT to Wed, 27 Aug 2025 15:08:04 GMT -
Rating 8
- Innovation 6
- Information 5
- Rumor -3
